Ocular Therapeutix Inc.

Last updated September 27, 2026

Organization details

Legal name
Ocular Therapeutix Inc.
Former names
I-Therapeutix Inc
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Bedford
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
OCUL
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001393434

Board of directors

Chief executives

Antony C. Mattessich · President and CEO
Dates unknown

Director election results

Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

4 of this board's directors also sit on 6 other boards. 5 are in the same sector.

Network of Ocular Therapeutix Inc.'s board connections Aura Biosciences Inc. Aura Biosciences Inc. Harrow Inc. Harrow Inc. LENSAR Inc. LENSAR Inc. Opus Genetics Inc. Opus Genetics Inc. TransMedics Group Inc. TransMedics Group Inc. Watts Water Technologies Inc. Watts Water Technologi... Adrienne L. Graves Adrienne L. Graves Antony C. Mattessich Antony C. Mattessich Merilee Raines Merilee Raines Richard L. Lindstrom M.D. Richard L. Lindstrom... Ocular Therapeutix Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$461,354
1 purchase by 1 insider
Sold, last 12 months
$3,250,061
29 sales by 8 insiders
Date Insider Transaction Shares Price Value
Nov 6, 2026 Riad Sherif Director Grant or award +28,000 — —
Nov 5, 2026 Saroj Namrata Officer (Chief Business Officer) Open-market sale −35,370 $6.55 $231,674
Oct 8, 2026 Anderman Todd Officer (Chief Legal Officer) Open-market sale −11,984 $7.29 $87,363
Oct 2, 2026 Jeffrey S. Heier Officer (Chief Scientific Officer) Open-market sale −10,869 $7.05 $76,626
Oct 2, 2026 Kaiser Peter Officer (Chief Development Officer) Open-market sale −9,990 $7.05 $70,430
Aug 31, 2026 Notman Donald Officer (Chief Operating Officer) Open-market sale −1,099 $10.24 $11,254
Aug 25, 2026 Pravin Dugel Director, Officer (See Remarks) Gift −50,092 — —
Aug 25, 2026 Pravin Dugel Director, Officer (See Remarks) Gift +50,092 — —
Aug 24, 2026 Pravin Dugel Director, Officer (See Remarks) Open-market sale −21,649 $10.77 $233,160
Aug 24, 2026 Jeffrey S. Heier Officer (Chief Scientific Officer) Open-market sale −3,296 $10.78 $35,531
Aug 24, 2026 Kaiser Peter Officer (Chief Development Officer) Open-market sale −3,035 $10.77 $32,687
Aug 24, 2026 Nayak Sanjay Officer (Chief Strategy Officer) Open-market sale −1,897 $10.78 $20,450
Jun 16, 2026 Pravin Dugel Director, Officer (See Remarks) Gift −50,092 — —
Jun 16, 2026 Pravin Dugel Director, Officer (See Remarks) Gift +50,092 — —
Jun 10, 2026 Charles M. Warden Director Grant or award +14,000 — —

Organizations in the same sector, closest in location and size first.

Questions about Ocular Therapeutix Inc.

Who is the CEO of Ocular Therapeutix Inc.?

Antony C. Mattessich is Ocular Therapeutix Inc.'s President and CEO.

How many directors are on Ocular Therapeutix Inc.'s board?

Ocular Therapeutix Inc.'s board has 10 directors: Adrienne L. Graves, Antony C. Mattessich, Charles M. Warden, Jeffrey S. Heier, Leslie J. Williams, Merilee Raines, Pravin Dugel, Riad Sherif, Richard L. Lindstrom M.D. and Seung Suh Hong.

Are Ocular Therapeutix Inc. insiders buying or selling shares?

Over the last 12 months, Ocular Therapeutix Inc. insiders bought $461,354 of shares in 1 purchase and sold $3.3 million of shares in 29 sales on the open market, as reported to the SEC on Forms 4 and 5.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="ocular-therapeutix-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.